Drug Profile
Eluxadoline - AbbVie
Alternative Names: JNJ-27018966; Mu Delta; TRUBERZI; VIBERZILatest Information Update: 01 Oct 2021
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica
- Developer AbbVie
- Class Amides; Benzoic acids; Imidazoles; Irritable bowel syndrome therapies; Small molecules
- Mechanism of Action Opioid delta receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Irritable bowel syndrome
Most Recent Events
- 13 Aug 2021 Phase-III clinical trials in Irritable bowel syndrome (In adolescents, In children) in USA (PO) (NCT04880876)
- 18 May 2021 AbbVie plans a phase III long term safety trial for Irritable bowel syndrome diarrhoea-predominant (In adolescents, In children) (PO) in May 2021 (NCT04880876)
- 11 Oct 2020 Pooled efficacy data from two phase III trial in Irritable bowel syndrome presented at the 28th United European Gastroenterology Week (UEG-2020)